AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

R-PMDT Regimen in Newly Diagnosed PCNSL

RecruitingPhase 2Ages 18 Years - anyAllZou Dehui
💬

In plain words

What the trial is, and whether it could suit you

A total of six cycles of the R-PMDT regimen (rituximab, pirtobrutinib, high-dose methotrexate, dexamethasone, and thiotepa) will be administered to patients with newly diagnosed primary central nervous system lymphoma (PCNSL). The primary objective is to assess the overall response rate (ORR) of R-PMDT. Secondary objectives include evaluating the complete response rate, progression-free survival (PFS), overall survival (OS), and safety.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Newly diagnosed primary central nervous system diffuse large B-cell lymphoma * Adequate hematologic function: ANC ≥1.0×10⁹/L, PLT ≥75×10⁹/L * Adequate hepatic function: ALT/AST ≤3×ULN; total bilirubin ≤1.5×ULN * Adequate renal function: serum creatinine ≤2×ULN or CrCl ≥40 mL/min * LVEF ≥55% by echocardiography * Baseline oxygen saturation \>92% on room air * Expected survival ≥3 months Exclusion Criteria: * Prior anti-lymphoma therapy other than corticosteroids. * Uncontrolled significant cardiovascular or cerebrovascular disease. * Uncontrolled active systemic bacterial, fungal, or viral infection. * Active hepatitis B and/or active hepatitis C (HCV RNA positive). Patients with positive hepatitis B surface antigen and/or core antibody but HBV-DNA \< 1000 IU/mL may be included and should receive concurrent oral antiviral prophylaxis against HBV reactivation. * Hypersensitivity to any study drug or its components. * Other active malignancy, except for adequately controlled non-melanoma skin cancer, in situ carcinoma, or malignancy that has been in complete remission for ≥5 years. * Pregnant or lactating women. Fertile patients unwilling to use effective contraception. * Other conditions deemed inappropriate by the investigator.
💊

What it tests

  • R-PMDT
📍

Where

1 site
Institute of Hematology & Blood Diseases Hospital
Tianjin, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy